Related Experiment Videos
Preliminary experience with aspirin for anticoagulation in children with prosthetic cardiac valves
Insights
Aspirin effectively prevents clots and bleeding in children with prosthetic heart valves, offering a safer alternative to warfarin. This study highlights aspirin
Area of Science:
- Pediatric Cardiology
- Cardiovascular Surgery
- Thrombotic Disease Management
Background:
- Prosthetic heart valves in children require long-term anticoagulation.
- Warfarin is a common anticoagulant but carries bleeding risks.
- Alternative anticoagulation strategies are needed for pediatric patients.
Purpose of the Study:
- To evaluate the efficacy and safety of aspirin (with or without dipyridamole) versus warfarin in pediatric patients with prosthetic cardiac valves.
- To assess the incidence of thrombotic, embolic, and bleeding complications in children on aspirin therapy.
- To compare outcomes with existing literature on warfarin use.
Main Methods:
- Retrospective review of 24 pediatric patients (ages 1-18) undergoing 27 valve replacement surgeries.
- Analysis of anticoagulation therapy: warfarin vs. aspirin (with or without dipyridamole).
- Follow-up for thrombotic, embolic, and bleeding events, and late mortality.
Main Results:
- 18 patients received aspirin (with or without dipyridamole); 5 received warfarin.
- No thrombotic, embolic, or bleeding complications were observed in the aspirin group over a mean follow-up of 20.4 months.
- Two late deaths occurred in the aspirin group (one cardiac).
Conclusions:
- Aspirin (with or without dipyridamole) appears to be a safe and effective anticoagulant for children with prosthetic cardiac valves.
- Aspirin offers protection against thromboemboli while avoiding the hemorrhagic complications associated with warfarin.
- Further research may support aspirin as a preferred anticoagulant in this pediatric population.
Abstract:
Twenty-four children (ages 1 to 18 years, mean 12.2 years) underwent 27 operations for aortic, mitral, or combined aortic and mitral valve replacement. There was 1 operative death. Of the 23 operative survivors (12 aortic, 8 mitral, 3 combined valve replacement), only 5 were given warfarin for long-term anticoagulation. The remaining 18 (10 aortic, 8 mitral valve replacement) were given aspirin (plus dipyridamole in 5). Twelve of the 18 had at least one mechanical valve (11 Björk-Shiley and Beall valves; 1 Björk-Shiley valve was replaced with a Beall disc valve as the child grew). These 18 patients were followed for 1 to 59 months (mean, 20.4 months). There was no thrombotic, embolic, or bleeding complications. There were 2 late deaths (one cardiac). Review of the available literature indicates that in children with prosthetic cardiac valves, aspirin (with or without dipyridamole) provides adequate protection against thromboemboli and avoids the hemorrhagic complications associated with warfarin.